

## Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-month Data

**Authors:** Kim A. Papp<sup>1</sup>, Melinda Gooderham<sup>2</sup>, Ignacio Dei-Cas<sup>3</sup>, Adriana LopezTello<sup>4</sup>, Juan C. Garcia-Rodriguez<sup>5</sup>, Carmen Yris Taveras<sup>6</sup>, Azucena Hernández Rousselin<sup>7</sup>, Alberto Lavieri<sup>8</sup>, Mónica Maiolino<sup>9</sup>, Delfina Guadalupe Villanueva Quintero<sup>10</sup>, Lenka Rihakova<sup>11</sup>, Mariano Salibe<sup>12</sup>, Wilfran Pertuz<sup>13</sup>

### Affiliations:

1. K Papp Clinical Research and Probit Medical Research, Waterloo, ON, Canada
2. SKiN Centre for Dermatology and Probit Medical Research, Peterborough and Queen's University, Kingston, ON, Canada
3. HIGA Presidente Perón, Servicio de Dermatología; Facultad Medicina UBA; Psoriasis BsAs. Buenos Aires, Argentina
4. NEKI Servicios Medicos, Vicente Guerrero, Toluca, Estado de México, Mexico
5. DermaAdvance Center, México City, Mexico
6. Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago De Los Caballeros, Dominican Republic
7. Hospital Roosevelt, Calzada Roosevelt, Guatemala City, Guatemala
8. Private Clinic, Ciudad Autónoma de Buenos Aires, Argentina
9. Consultorios médicos Dr Bouzo, Ciudad Autónoma de Buenos Aire, Argentina
10. Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflammatorias) Sociedad Civil, Guadalajara, Jalisco, Mexico
11. Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
12. Novartis Argentina S.A., Ciudad Autónoma de Buenos Aires, Argentina
13. Novartis Pharma Logistics, Inc., Panama, Costa del Este, Panama City, Panama

**Corresponding author:** Azucena Hernández Rousselin

**Address:** Hospital Roosevelt. Calzada Roosevelt y 5ta calle, zona 11. Consulta Externa II, Dermatología. Guatemala, Guatemala

**Email:** susyderma@gmail.com

**Contact number:**(502) 5017-0433

**Index**

Supplementary Table S1. Psoriasis therapies at baseline	4
Supplementary Table S2. Safety tables for all SAEs by SOC and PT	6

Supplementary Table S1. Psoriasis therapies at baseline

Type of prior psoriasis therapy <sup>a</sup>	Secukinumab N = 89	Other Tx N = 98	Overall N = 187
<b>Number of subjects with any current psoriasis therapies, n (%)</b>	75 (84.3)	84 (85.7)	159 (85.0)
<b>Biologic systemic therapy</b>	75 (84.3)	42 (42.9)	117 (62.6)
Secukinumab	75 (84.3)	0 (0.0)	75 (40.1)
Adalimumab	0 (0.0)	27 (27.6)	27 (14.4)
Ustekinumab	0 (0.0)	7 (7.1)	7 (3.7)
Etanercept	0 (0.0)	5 (5.1)	5 (2.7)
Guselkumab	0 (0.0)	2 (2.0)	2 (1.1)
Ixekizumab	0 (0.0)	1 (1.0)	1 (0.5)
<b>Non-biological systemic therapy</b>	3 (3.4)	38 (38.8)	41 (21.9)
Methotrexate	1 (1.1)	28 (28.6)	29 (15.5)
Folic acid	1 (1.1)	9 (9.2)	10 (5.3)
Methotrexate sodium	1 (1.1)	6 (6.1)	7 (3.7)
Ciclosporin	1 (1.1)	3 (3.1)	4 (2.1)
Acitretin	0 (0.0)	1 (1.0)	1 (0.5)
Calcipotriol	0 (0.0)	1 (1.0)	1 (0.5)
Cefalexin	0 (0.0)	1 (1.0)	1 (0.5)
Clobetasol	0 (0.0)	1 (1.0)	1 (0.5)
Diclofenac	0 (0.0)	1 (1.0)	1 (0.5)
Sulfasalazine	0 (0.0)	1 (1.0)	1 (0.5)
<b>Photo chemotherapy</b>	0 (0.0)	1 (1.0)	1 (0.5)
Psoralens for topical use	0 (0.0)	1 (1.0)	1 (0.5)
<b>Phototherapy</b>	0 (0.0)	1 (1.0)	1 (0.5)
Psoralens for topical use	0 (0.0)	1 (1.0)	1 (0.5)
<b>Topical</b>	1 (1.1)	14 (14.3)	15 (8.0)
Betamethasone dipropionate; calcipotriol	0 (0.0)	5 (5.1)	5 (2.7)
Calcipotriol	0 (0.0)	2 (2.0)	2 (1.1)
Clobetasol	0 (0.0)	2 (2.0)	2 (1.1)
Salicylic acid	0 (0.0)	2 (2.0)	2 (1.1)
Urea	0 (0.0)	2 (2.0)	2 (1.1)
Antipsoriatics for topical use	0 (0.0)	1 (1.0)	1 (0.5)
Beeswax; cetyl palmitate; light liquid paraffin	0 (0.0)	1 (1.0)	1 (0.5)
Betamethasone dipropionate; miconazole nitrate	0 (0.0)	1 (1.0)	1 (0.5)
Clobetasol propionate	0 (0.0)	1 (1.0)	1 (0.5)
Coal tar	0 (0.0)	1 (1.0)	1 (0.5)
Cocos nucifera oil	0 (0.0)	1 (1.0)	1 (0.5)
Methotrexate	0 (0.0)	1 (1.0)	1 (0.5)

Paraffin soft	1 (1.1)	0 (0.0)	1 (0.5)
Shampoos	0 (0.0)	1 (1.0)	1 (0.5)
Tacrolimus	0 (0.0)	1 (1.0)	1 (0.5)
Triamcinolone	1 (1.1)	0 (0.0)	1 (0.5)

*mITT* modified intent-to-treat population, *N* total number of patients, *n* number of patients, *Other Tx* other approved therapies, *SEC* secukinumab

<sup>a</sup>All psoriasis therapies are coded and summarised according to their generic therapy names using WHO Drug classification. A participant may have received more than one type of therapy. The therapies under the same generic therapy name are counted only once. Percentages are based on the total number of *mITT* participants in each treatment cohort

Supplementary Table S2. Safety tables for all SAEs by SOC and PT

SAEs by SOC and PT, <i>n</i> (%)	Secukinumab <i>N</i> = 89	Other Tx <i>N</i> = 98	Overall <i>N</i> = 187
<b>Cardiac disorders</b>	0 (0.0)	1 (1.0)	1 (0.5)
Cardiac failure	0 (0.0)	1 (1.0)	1 (0.5)
Hypertensive heart disease	0 (0.0)	1 (1.0)	1 (0.5)
<b>Gastrointestinal disorders</b>	1 (1.1)	0 (0.0)	1 (0.5)
Colitis ulcerative	1 (1.1)	0 (0.0)	1 (0.5)
Large intestine perforation	1 (1.1)	0 (0.0)	1 (0.5)
<b>Hepatobiliary disorders</b>	1 (1.1)	0 (0.0)	1 (0.5)
Hepatitis fulminant	1 (1.1)	0 (0.0)	1 (0.5)
<b>Infections and infestations</b>	1 (1.1)	1 (1.0)	2 (1.1)
Cellulitis	0 (0.0)	1 (1.0)	1 (0.5)
Enterococcal infection	1 (1.1)	0 (0.0)	1 (0.5)
<b>Investigations</b>	1 (1.1)	0 (0.0)	1 (0.5)
Hematocrit decreased	1 (1.1)	0 (0.0)	1 (0.5)
<b>Metabolism and nutrition disorders</b>	1 (1.1)	0 (0.0)	1 (0.5)
Hypokalemia	1 (1.1)	0 (0.0)	1 (0.5)
<b>Neoplasms benign, malignant and unspecified (including cysts and polyps)</b>	1 (1.1)	0 (0.0)	1 (0.5)
Breast cancer	1 (1.1)	0 (0.0)	1 (0.5)
<b>Renal and urinary disorders</b>	0 (0.0)	1 (1.0)	1 (0.5)
Focal segmental glomerulosclerosis	0 (0.0)	1 (1.0)	1 (0.5)
<b>Surgical and medical procedures</b>	0 (0.0)	1 (1.0)	1 (0.5)
Hospitalisation	0 (0.0)	1 (1.0)	1 (0.5)
<b>Vascular disorders</b>	0 (0.0)	1 (1.0)	1 (0.5)
Hypertensive crisis	0 (0.0)	1 (1.0)	1 (0.5)

*n* number of patients, *N* total number of patients, *Other Tx* other approved therapies, *PT* preferred term, *SAEs* serious adverse events, *SEC* secukinumab, *SOC*, system organ class